Astraveus products

Hematopoietic stem cells (HSCs) are mothers to all blood cells including erythrocytes and lymphocytes. We develop high quality genetically edited HSCs to cure an undisclosed hereditary blood disease. This development will be translatable: genetically edited HSCs can be used to treat multiple genetic diseases, including hemoglobinopathies and immune deficiencies.

Macrophages are versatile cells. They exhibit abilities to survive solid tumor microenvironment, to trigger inflammation and to absorb and digest debris or infected cells. CAR-Macrophages (CAR-M) are artificially directed against a cancerous target by a chimeric antigen receptor. CAR-M are still in their clinical infancy, however specific abilities of macrophages make them a promising approach to treat solid tumors resisting to available therapies. We are currently in the early-stage development of CAR-M with our miniaturization and optimization technologies.

In healthy patients T cells detect and kill sick cells. Cancer cells escape T cells recognition thanks to mutations. CAR-T cells (T cells equipped with a Chimeric Antigen Receptor) are artificially hardcoded to recognize and kill cancer cells. Multiple CAR-T therapies are commercially available but their access is limited by low manufacturing throughput and high prices. We use our exclusive optimization and miniaturization technologies to improve CAR-T therapies in clinically validated applications to boost their accessibility.